ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Experts Discuss the Latest Studies on ADCs for Lung Cancer at ASCO 2024

In a comprehensive discussion on the role of antibody-drug conjugates (ADCs) in the treatment of lung cancer at the American Society of Clinical Oncology (ASCO)

July 11, 2024

Pacific Biosciences to lay off 195 employees as part of cost cuts

Dive Brief: Pacific Biosciences said last week that it will lay off about 195 employees, or nearly 25% of its workforce, as part of a

May 14, 2024

Targeted drug therapy shows promise for ulcerative colitis remission

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at

September 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.